Papillomavirus Vaccines Clinical Trial
Official title:
Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017)
Currently there are no standards for healthcare worker vaccination with the HPV, Gardasil-9 vaccine. For health care workers, the CDC only recommends for vaccination against hepatitis B, influenza virus, Measles, Mumps and Rubella (MMR), Chickenpox (Varicella), Tetanus, Diptheria, and Pertussis (Tdap), and meninogococcal infections6
Initial antibody titers will be measured immediately prior to initial vaccination (month 0). This will entail a blood-draw sample (less than 1 teaspoon) that will be sent to FOCUS labs for evaluation. This will be paid for by funding received from Merck. The three-dose vaccination schedule will be followed with injections at month 0, 2, and 6. Gardasil 9 dosing will be per the recommended and approved labeled guidelines. Post-vaccination titers would be measured at month 7, which is in alignment with the methods of previous studies. This will entail a blood-draw sample (less than 1 teaspoon) that will be sent to FOCUS labs for evaluation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00359619 -
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
|
Phase 2 | |
| Completed |
NCT00250276 -
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
|
Phase 3 | |
| Completed |
NCT01031069 -
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
|
Phase 4 | |
| Recruiting |
NCT05266898 -
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
|
Phase 4 | |
| Completed |
NCT03763565 -
Effectiveness of HPV Vaccine in Thai Adult Women
|
||
| Completed |
NCT00877877 -
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
|
Phase 3 | |
| Completed |
NCT00811798 -
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
|
Phase 3 | |
| Recruiting |
NCT05884697 -
Let's K-Talk - HPV Study for Ethnic Koreans
|
N/A | |
| Completed |
NCT00637195 -
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
|
Phase 3 | |
| Completed |
NCT00798265 -
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
|
Phase 1 | |
| Completed |
NCT00423046 -
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
|
Phase 3 | |
| Completed |
NCT00294047 -
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
|
Phase 3 | |
| Recruiting |
NCT04469569 -
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
|
N/A | |
| Not yet recruiting |
NCT04671823 -
Changes in the Prevalence of Oncogenic HPV Types
|
||
| Active, not recruiting |
NCT05148559 -
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
|
N/A | |
| Completed |
NCT02370459 -
AFIX to Improve HPV Vaccination
|
N/A | |
| Completed |
NCT00456807 -
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
|
Phase 3 | |
| Completed |
NCT03501992 -
Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
|
N/A |